Anticoccidial Drugs Market

The global Anticoccidial Drugs Market is valued at USD 184.3 Million in 2023 and is projected to reach a value of USD 268.1 Million by 2032 at a CAGR (Compound Annual Growth Rate) of 4.3% between 2024 and 2032.

Key highlights of Anticoccidial Drugs Market

• The North American region contributed to a revenue share of 43.2% in 2023.
• The Asia Pacific is predicted to increase at the fastest rate in the anticipated years, with a maximum CAGR of more than 5.7%.
• In 2023, the Synthetic Drugs contributed significantly to the market expansion with 80.4% of the overall revenue share.
• In 2023, the Coccidiostatic category held a notable 78.2% Anticoccidial Drugs market revenue share.
• Based on Animal, the companion animals segment accounted to have the substantial growth of the Anticoccidial Drugs market in 2023 with a revenue share of 58.4%.
• According to the American Pet Products Association's 2023-2022 National Pet Owners Survey, around 90.5 million households in the United States, comprising 70% of the total, have pets. This represents a notable rise from the 1988 survey, which reported only 56% of U.S. households owning pets, and a progression from 2019's figure of 67%.

Anticoccidial Drugs Market: Regional Overview

With a revenue share of 43.2% in 2023, the North American region contributed the most to the market's growth and is predicted to continue leading the way. This is due to factors such as the increasing trend of animal adoption and higher spending on animal healthcare within the region. North America is a major player in the worldwide meat, dairy, and egg sectors, accounting for about 80 billion animal slaughters per year. 98% of all animals utilized by humans in various industries are those reared for food, according to the FAO. The data shows that acute diarrhea is not the leading cause of diagnosed cases in beef and dairy calves but relatively high coccidial oocyst counts. This highlights the urgent need for effective solutions in the North American livestock industry. The need to address coccidiosis issues arises from North America's continued leadership in animal husbandry worldwide.

U.S. Anticoccidial Drugs Market Overview

The U.S. Anticoccidial Drugs Market is valued at USD 48.57 Million in 2023 and is projected to reach a value of USD 67.10 Million by 2032 at a CAGR (Compound Annual Growth Rate) of 3.7% between 2024 and 2032. The United States Anticoccidial Drugs Market is accounted for significant growth, primarily driven by the nationwide surge in the trend of pet adoption. According to the recent findings from the 2023-2024 American Pet Products Association (APPA) National Pet Owners Survey, 66% of U.S. households, totaling 86.9 million, own pets. This includes 65.1 million households with dogs, 46.5 million with cats, and 2.2 million with horses. The surge in the adoption of companion animals, which are inherently more susceptible to fungal diseases like coccidiosis, is anticipated to fuel the demand for Anticoccidial Drugs in the foreseeable future.

The global Anticoccidial Drugs market can be categorized as Drug Class, Drug Action, Animal, and Region.

Anticoccidial Drugs Market: Drug Class Overview

In 2023, the synthetic Drugs segment led the market and accounted for a revenue share of 80.4%. Based on Drug Class, the Anticoccidial Drugs market is divided into Ionophore and Synthetic Drugs. Synthetic drugs offer several advantages over other types of anticoccidials. They are chemically synthesized compounds specifically designed to target and kill coccidian parasites. This targeted approach ensures high efficacy and specificity, reducing the risk of resistance development. Synthetic medications are useful for commercial chicken production because they facilitate easy administration and accurate dosage. Additionally, the creation of novel synthetic medications with enhanced effectiveness and less adverse effects has further fuelled this market's expansion. Pharmaceutical companies invest in research and development to create novel compounds with superior antiparasitic properties. These advancements have facilitated the availability of a wide range of synthetic drugs in the market, providing poultry producers with more options for disease control.

Anticoccidial Drugs Market: Drug Action Overview

The Coccidiostatic segment accounted for the most significant revenue share of 78.2% in 2023. By Drug Action, the Anticoccidial Drugs market is classified into Coccidiostatic and Coccidiocidal. The poultry industry has grown as a result of consumer demand for chicken goods including meat and eggs. As coccidiosis is a significant threat to poultry production, there is a growing need for effective prevention and control measures, including coccidiostats. Additionally, the surge in the cattle business can be attributed to the growing world population and the consequent demand for food sources that are rich in protein. As a result, there is a greater focus on improving the productivity and efficiency of livestock operations, including preventing and controlling diseases like coccidiosis. Coccidiostats are essential for accomplishing these objectives since they minimize the losses brought on by coccidiosis while also enhancing the general well-being and productivity of the animals.

Anticoccidial Drugs Market: Animal Overview

The companion animals segment accounted for the significant growth of the market with a revenue share of 58.4%. Based on Animal, the Anticoccidial Drugs market is classified into Livestock Animals (Cattle, Poultry, Other Livestock Animals) and Companion Animals (Dogs, Cats, Other Companion Animals). There has been a significant increase in pet ownership worldwide. People are increasingly looking to own pets, such as dogs and cats, for companionship and emotional support. This rise in pet ownership has led to increased demand for veterinary services, including treating parasitic infections like coccidiosis. As a result, the demand for Anticoccidial Drugs for companion animals has also improved. In addition, there has been a progressive shift in pet owners' mindset towards healthcare and preventive measures for their pets. Nowadays, more and more pet owners are aware of the different illnesses and infections, including coccidiosis, that can afflict their animals. They are more willing to invest in preventive measures and treatments to ensure the health and well-being of their pets. This has increased sales and consumption of Anticoccidial Drugs in the companion animal market.

Key Trends

1. The increasing focus on animal wellbeing has increased the need for feed additives to prevent and control coccidiosis. Manufacturers are creating innovative drugs in the form of feed additives to enhance animal growth and productivity while reducing disease occurrences, such as Elanco Animal Health's BMD® (Bacitracin Methylene Disalicylate), which effectively combats coccidiosis in poultry and improves intestinal health and feed efficiency.
2. Due to concerns about antibiotic resistance, there is an increasing trend towards non-antibiotic alternatives like herbal extracts, essential oils, probiotics, and organic acids to manage coccidiosis in animals. CIBENZA® DP100, a non-antibiotic product from Novus International, helps manage coccidiosis in poultry and improves gut health.
3. Vaccination against coccidiosis is on the rise as it reduces reliance on chemical treatments and stimulates the immune system of animals to develop protection, exemplified by HIPRACOX®.
4. Companies in the Anticoccidial Drugs market actively invest in R&D to create new drugs, enhance existing products, and develop eco-friendly solutions for coccidiosis management, such as Zoetis Inc.'s research program focused on innovative anticoccidial products.

Premium Insights

As per the 2023–2024 APPA National Pet Owners Survey, 86.9 million households in the United States are home to 66% of pets. The most common pets are dogs, owned by 65.1 million households, followed by cats (46.5 million households) and freshwater fish (11.1 million households). Small animals (6.7 million homes), reptiles (6.0 million households), saltwater fish (2.2 million households), birds (6.1 million households), and horses (2.2 million households) are some of the other common pet species. This diverse range of pet ownership, coupled with an analysis of pet ownership trends across generations, highlights the potential of the Anticoccidial Drugs Market. Generation Z, comprising 16% of current pet owners, is paving the way for Millennials, who constitute 33% of pet owners. Baby Boomers make up 24% of the contribution, followed closely by Generation X at 25%, and the Builders at 2%. The strong bond between households and their pets indicates a high demand for Anticoccidial Drugs, emphasizing the need for innovative solutions to protect the health and well-being of these beloved animal companions.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Dynamic Pet Ownership Patterns and Rising Global Awareness Navigate the Boom in Anticoccidial Drugs Market Growth

The Anticoccidial Drugs Market is set to grow significantly due to the changing dynamics of pet ownership among different generations. An in-depth analysis shows that Millennials are the most extensive pet owners, accounting for 33% of the current pet population. Generation X and Baby Boomers also have a significant presence in the market, with 25% and 24%, respectively. Generation Z comprises 16% of pet owners, while Builders represent 2%. This strong connection between households and their pets creates a steady demand for Anticoccidial Drugs, as people want to ensure the health and well-being of their beloved animals. The trend of increasing companion animal ownership is not limited to the United States; Canada and Mexico are also experiencing growth. According to recent Pet Keen data, 38% of Canadian households owned a cat, and 35% owned a dog in 2021, indicating a willingness to invest in pet healthcare. The frequency of coccidiosis in dogs and cats is also bringing attention from pet owners, which is anticipated to fuel demand for novel medications and support the market's overall expansion for anticoccidial pharmaceuticals.

Evolving Coccidiosis Challenges Thrives the Demand for Anticoccidial Drugs Market

The Anticoccidial Drugs Market is experiencing a high demand due to the widespread problem of coccidiosis, especially in farms with poor hygiene practices. Effective control tactics are necessary for coccidiosis, which is influenced by age, breed, health circumstances, and biosecurity measures. Biosecurity practices are essential in preventing and managing coccidiosis. There are nearly 20 different Eimeria species found in cattle feces worldwide, showing that this issue is widespread. Clinical infection usually starts at 1-2 months of age, with cecal coccidiosis being the most severe form, causing up to 50% of deaths in flocks. In 2023, there was a decrease in the occurrence of Eimeria acervulina in birds compared to the previous year, but there was a concerning five-fold increase in gross Eimeria tenella lesions. This complicated situation regarding coccidiosis highlights the need for innovative and targeted Anticoccidial Drugs to address the evolving challenges in the poultry industry.

Competitive Landscape

Key players in the Anticoccidial Drugs Market are making strategic moves and innovative endeavors. For instance, in February 2021, Merck Animal Health demonstrated its commitment to advancing the industry by acquiring PrognostiX Poultry Limited, operating as Poultry Sense Ltd. This move shows Merck's interest in expanding its portfolio and emphasizes the importance of specialized environmental and health monitoring solutions for the poultry sector. Additionally, with about 90.5 million American families keeping pets, the demand for pet ownership is rising, creating a lucrative market for anticoccidial medications. In March 2021, Elanco Animal Health Inc. introduced two anticoccidial feed additives in Sri Lanka, showing the global expansion of their product offerings. Thanks to recent developments and strategic acquisitions, Merck Animal Health and Elanco Animal Health Inc. have emerged as leaders in the Anticoccidial Drugs market. They are poised to address changing market needs, promote innovation, and drive future market growth.

The key players in the global Anticoccidial Drugs market include - Bayer AG (Germany), Bioproperties Pty Ltd. (Australia), Boehringer Ingelheim International GmbH (Germany), Ceva Sante Animale (France), Cronus Pharma LLC (U.S.), Elanco Animal Health Inc. (U.S.), Huvepharma EOOD (Bulgaria), Impextraco NV (Belgium), Kemin Industries Inc. (U.S.), LABORATORIOS HIPRA SA (Spain), Merck and Co. Inc. (U.S.), Novartis AG (Switzerland), Phibro Animal Health Corp. (U.S.), Qilu Animal Health Products Co. Ltd. (China), Vetoquinol SA (France), VH Group (India), Virbac (France), Zoetis Inc. (U.S.) among others.

Recent Development

• In January 2024, Boehringer Ingelheim introduced a new poultry coccidiosis vaccine called Vaxxilive Cocci 3. This vaccine, previously known as Hatchpak Cocci III, is designed to prevent coccidiosis in poultry. It serves as an alternative to in-feed drugs and works by activating the bird's natural immune system without harming its body tissues.
• In June 2023, Amlan® International, a company specializing in animal nutrition and health and owned by Oil-Dri® Corporation of America, has successfully acquired the remaining non-controlling interest of Agromex Importaciones, S.A. de C.V. The acquisition was finalized on May 12, 2023. As a result, Amlan now has complete ownership of its subsidiary in Mexico, which strengthens its presence in the Mexican market.